Edition:
United States

Roche Holding AG (RO.S)

RO.S on Swiss Exchange

244.40CHF
6:30am EDT
Change (% chg)

CHF1.20 (+0.49%)
Prev Close
CHF243.20
Open
CHF244.80
Day's High
CHF244.80
Day's Low
CHF243.60
Volume
5,643
Avg. Vol
29,207
52-wk High
CHF255.00
52-wk Low
CHF209.40

Chart for

About

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas:... (more)

Overall

Beta: 1.01
Market Cap(Mil.): CHF207,339.70
Shares Outstanding(Mil.): 862.56
Dividend: 8.30
Yield (%): 3.46

Financials

  RO.S Industry Sector
P/E (TTM): 19.71 28.29 30.45
EPS (TTM): 12.18 -- --
ROI: 21.29 12.92 12.63
ROE: 41.72 14.94 14.82

Roche's Alecensa latest beneficiary of faster China drug approvals

ZURICH Roche's Alecensa lung cancer medicine became the latest beneficiary of China's efforts to speed up approvals in the world's second-biggest drug market, which is gaining importance for global pharmaceuticals companies' growth plans.

2:25am EDT

Roche's Alecensa latest beneficiary of faster China drug approvals

ZURICH, Aug 20 Chinese regulators are speeding up drug approvals, with Roche's Alecensa cancer medicine the latest beneficiary in a market that is growing increasingly important for international pharmaceuticals companies' growth plans.

1:11am EDT

Pfizer bets on biotech flu vaccine in $425 million BioNTech alliance

FRANKFURT Pfizer has agreed to pay German biotech firm BioNTech up to $425 million in an alliance to develop more effective influenza jabs, the latest among several major pharma companies to bank on a promising new genetic approach.

Aug 16 2018

Pfizer bets on biotech flu vaccine in $425 mln BioNTech alliance

FRANKFURT, Aug 16 Pfizer has agreed to pay German biotech firm BioNTech up to $425 million in an alliance to develop more effective influenza jabs, the latest among several major pharma companies to bank on a promising new genetic approach.

Aug 16 2018

BRIEF-Roche Canada Says Health Canada Approves Hemlibra For Hemophilia A Patients With Inhibitors

* HEALTH CANADA APPROVES HEMLIBRA® FOR HEMOPHILIA A PATIENTS WITH INHIBITORS Source text for Eikon: Further company coverage:

Aug 14 2018

Bank DNB switches US, Europe mutual funds to index tracking

OSLO, Aug 14 Norwegian bank DNB will switch its mutual funds for U.S. and European stocks to index tracking from active management on Aug. 16, it said on Tuesday.

Aug 14 2018

Swiss stocks - Factors to watch on July 27

ZURICH, July 27The Swiss blue-chip SMI was seen opening 0.1 percent down at 9,135 points on Friday, according to premarket indications by bank Julius Baer .

Jul 27 2018

UPDATE 1-Switzerland's Vontobel lifts 2020 goals after buying private bank Notenstein

* CEO sees profitability hike, despite difficult markets (Adds comment from CEO, details throughout)

Jul 27 2018

Roche lifts veil on patent that earned it billions but soon expires

ZURICH Roche on Thursday lifted its veil of secrecy over a patent that has reaped billions of dollars over the years but is due to expire on Dec. 18, depriving the Swiss drugmaker of a key source of income.

Jul 26 2018

Roche lifts veil on patent that earned it billions but soon expires

ZURICH, July 26 Roche on Thursday lifted its veil of secrecy over a patent that has reaped billions of dollars over the years but is due to expire on Dec. 18, depriving the Swiss drugmaker of a key source of income.

Jul 26 2018

Earnings vs. Estimates